It is a heartbreaking condition that robs children of their ability to walk, talk and recognise their loved ones and now the latest research has revealed the true impact of childhood dementia globally.
The new University of Chicago Healthy Aging & Alzheimer's Research Care (HAARC) Center will focus on building deep multidisciplinary expertise and bridging the gap between scientific disciplines to accelerate breakthroughs in cognitive resilience.
Using gene therapy to treat many neurologic diseases, such as Alzheimer’s and Parkinson’s, has long been a long-sought goal of researchers, but the blood-brain barrier has proven very difficult to cross.
Scientists have opened a new view into the workings of the brain and central nervous system, detecting a diverse set of important molecules known as lipoproteins. The most common protein on the particles is apolipoprotein E; one form of APOE puts people at higher risk of Alzheimer’s disease.
The Richmond, Virginia-based Red Gates Foundation recently committed $50 million to the Fralin Biomedical Research Institute at VTC to accelerate health sciences research at Virginia Tech. The gift is among the largest ever made to the university.
A three-year, $3.4 million grant to investigate how Alzheimer’s disease is connected to multiple chronic diseases has been awarded to UTHealth Houston researchers by the National Institute on Aging, part of the National Institutes of Health.
Scientists at St. Jude Children’s Research Hospital found that a subset of CD8+ T cells in the brain lessens the activation of microglia and limits disease pathology in a model of Alzheimer’s disease.
New research published in the Journal of the American Geriatrics Society indicates that antipsychotics are likely overprescribed and used inappropriately among patients with Alzheimer’s disease and related dementias (ADRD) receiving home health care, and such use is linked to worse patient outcomes.
SMU biology professor Zhihao Wu has received a $1.8 million, 5-year Maximizing Investigators' Research Award (MIRA) from the National Institutes of Health to determine if different quality control pathways in our bodies might be working together to repair damaged components in cells.
Researchers have received a U.S. patent for a novel method to identify therapeutic agents to treat addiction. The invention, related to the fields of pharmacology, medicine, neurology and psychiatry, targets the protein MBLAC1, which the Blakely lab identified as the mammalian form of a gene the group first identified in worms as a modifier of signaling by the neurotransmitter dopamine.
A groundbreaking study led by experts from Indiana University School of Medicine has shed new light on the genetic underpinnings of Alzheimer's disease.
A new Columbia Nursing study analyzes the performance of ADscreen, a computerized speech processing algorithm that is being developed to support clinicians in detecting and monitoring the progression of Alzheimer's disease and related dementias early.
With the help of a new grant from the National Institutes of Health for more than $2.6 million, Assistant Professor Timothy Huang, Ph.D., will continue his research on the role of the brain’s immune cells on the risk of developing Alzheimer’s disease.
Scientists at Wake Forest University School of Medicine are reporting results from a Phase I trial in an area of promising research for Alzheimer's disease—cellular senescence.
Neuroscience researchers at Wayne State University published a review article that confirms the usefulness of neurofilament light (NfL) blood levels to predict the likelihood and rate of progression of neurodegeneration in Alzheimer’s disease.
An Indiana University School of Medicine statewide project in collaboration with Indiana University Health was recently funded to support people living with dementia as well as their family care partners find more support and resources, thanks to a new $686,000 grant from the National Institute on Aging IMPACT Collaboratory.
Brent Forester, the Dr. Frances S. Arkin Chair of Psychiatry at Tufts University School of Medicine and psychiatrist-in-chief and chair of the Department of Psychiatry at Tufts Medical Center, focuses his research on geriatric psychiatry and neurocognitive disorders, such as Alzheimer’s disease and related dementias, late-life depression, and older adult bipolar disorder.
John Chappell, a cardiovascular scientist in the Center for Vascular and Heart Research at the Fralin Biomedical Research Institute at VTC, didn't quite believe what he was seeing.
Researchers have identified a way to assess brain activity in sleep that occurs in the earliest stages of Alzheimer’s disease, typically many years prior to developing symptoms of dementia.
En julio, salió al mercado el primer análisis de sangre directo al consumidor diseñado para evaluar el riesgo de un usuario de desarrollar la enfermedad de Alzheimer.
A new study by Indiana University School of Medicine researchers uses more genetically diverse mouse models to study the accumulation and spread of abnormal tau protein deposits in the brain.
Researchers analyzed health information on middle-aged and senior participants in the UK Biobank. They showed that those who took part in adult education classes had a 19% lower risk of developing dementia within five years of follow-up.
Researchers at RUSH are seeking volunteers to explore how a change in diet may improve brain health after a stroke. The study, called NOURISH — short for Nutrition Effects on Brain Outcomes and Recovery in Stroke After Hospitalization — aims to prevent cognitive and memory decline that is common in stroke survivors.
New results from researchers at UC San Diego School of Medicine suggest that intermittent fasting could be an effective treatment approach for Alzheimer’s disease.
In trials, the antipsychotic drug brexpiprazole (Rexulti) failed to provide a clinically meaningful benefit and increased the risk of death. Yet the US Food and Drug Administration (FDA) has fast tracked its approval, making Rexulti the first antipsychotic for treating agitation in elderly patients with dementia.
Only a small percentage of older adults who are in the early stages of Alzheimer’s disease meet the eligibility criteria to receive new monoclonal antibody treatments, drugs that target amyloid-ß plaques in the brain, an early sign of Alzheimer’s disease. The new research is published in the August 16, 2023, online issue of Neurology®, the medical journal of the American Academy of Neurology. Clinical trial results for these drugs are only available in people in the early symptomatic stages of the disease, mild cognitive impairment or mild dementia due to Alzheimer’s disease.
Prior vaccination against tetanus and diphtheria, with or without pertussis (Tdap/Td); herpes zoster (HZ), better known as shingles; and pneumococcus are all associated with a reduced risk for developing Alzheimer’s disease, according to new research from UTHealth Houston.
Dr. Heather Sandison, a leading expert in Alzheimer's Disease and Related Dementia (ADRD) care, has recently published a groundbreaking study in the Journal of Alzheimer's Disease, highlighting significant improvements in cognitive function among individuals with cognitive decline.
La inteligencia artificial (IA) está capturando la imaginación del público a medida que el ritmo de la innovación se acelera considerablemente y las herramientas de IA fáciles de usar ofrecen nuevas posibilidades para transformar industrias enteras.
A new study published in the Journal of Alzheimer’s Disease by a Virginia Tech Carilion School of Medicine faculty member shows that brain levels of dietary lutein, zeaxanthin, lycopene, and vitamin E in those with Alzheimer’s disease are half those in normal brains. Higher dietary levels of lutein and zeaxanthin have been strongly linked to better cognitive functions and lower risk for dementia or Alzheimer’s disease.
Artificial intelligence (AI) is capturing the public imagination as the pace of innovation accelerates sharply and easy-to-use AI tools offer new possibilities to transform whole industries.
Scientists at Université Laval and the University of Lethbridge have succeeded in reversing certain cognitive manifestations associated with Alzheimer's disease in an animal model of the disease.
Promising preclinical results from UC San Diego show hematopoietic stem cell therapy was effective in rescuing memory loss, neuroinflammation and beta amyloid build-up in a mouse model of Alzheimer’s disease.
People who take acid reflux medications called proton pump inhibitors for four-and-a-half years or more may have a higher risk of dementia compared to people who do not take these medications, according to new research published in the August 9, 2023, online issue of Neurology®, the medical journal of the American Academy of Neurology. This study does not prove that acid reflux drugs cause dementia; it only shows an association.
A team from the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) has demonstrated that tau PET - a novel imaging technique for visualising the tau protein - can predict cognitive decline in patients much better than the imaging techniques normally used.
Research from Saint Louis University School of Medicine finds that among patients 65 and older, a diagnosis of anxiety was significantly associated with an increased risk of dementia diagnosis, and benzodiazepine exposure was associated with a 28% increased risk of dementia.
The University of Miami Miller School of Medicine Department of Otolaryngology has received a new $3.2 million, five-year grant from the National Institutes of Health (NIH) to support their multidisciplinary translational research program on human genetic hearing loss (HL), a common sensory disorder affecting more than 28 million Americans.
By analyzing data from nearly 13,000 subjects who participated in a long-term aging study, Florida State University researchers found that an interviewer’s rating of a cognitively healthy person’s memory successfully predicted the likelihood of developing dementia over a 15-year period.
Black people and people living in less affluent neighborhoods—areas with higher poverty levels and fewer educational and employment opportunities— may be less likely to be seen at a memory care clinic compared to white people and people living in neighborhoods with fewer disadvantages, according to new research published in the August 2, 2023, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Members of minoritized racial or ethnic groups and people who live in less affluent neighborhoods are less likely than others to receive specialized care for dementia, including Alzheimer’s disease, a new study from Washington University School of Medicine in St. Louis indicates.
Accumulation and deposition of amyloid can cause a variety of neurodegenerative diseases, including Alzheimer's and Parkinson's disease. The degradation of this accumulation is the most widely accepted therapeutic strategy. The study on amyloid-β (Aβ) oligomers in vitro found that high-frequency terahertz (THz) wave at a specific frequency could be served as a physical, efficient, nonthermal denaturation way to delay the fibrotic process with a speed of 80 per cent.
With a $16 million grant from the National Institute on Aging, the University of California, San Francisco and the University of California, Irvine will work with community partners to improve the representation of Asian American, Native Hawaiian and Pacific Islander adults in research on aging, caregiving, and Alzheimer’s disease and related dementias.
A new study lends further weight to the idea that vision problems and dementia are linked. In a sample of nearly 3,000 older adults who took vision tests and cognitive tests during home visits, the risk of dementia was much higher among those with eyesight problems – including those who weren’t able to see well even when they were wearing their usual eyeglasses or contact lenses.
An interdisciplinary study found that both internet information gathering services have strengths and weaknesses for people seeking information about Alzheimer's disease and other forms of dementia.